» Articles » PMID: 38258390

High-Throughput Miniaturized Synthesis of PROTAC-Like Molecules

Overview
Journal Small
Date 2024 Jan 23
PMID 38258390
Authors
Affiliations
Soon will be listed here.
Abstract

The development of miniaturized high-throughput in situ screening platforms capable of handling the entire process of drug synthesis to final screening is essential for advancing drug discovery in the future. In this study, an approach based on combinatorial solid-phase synthesis, enabling the efficient synthesis of libraries of proteolysis targeting chimeras (PROTACs) in an array format is presented. This on-chip platform allows direct biological screening without the need for transfer steps.  UV-induced release of target molecules into individual droplets facilitates further on-chip experimentation. Utilizing a mitogen-activated protein kinase kinases (MEK1/2) degrader as a template, a series of 132 novel PROTAC-like molecules is synthesized using solid-phase Ugi reaction. These compounds are further characterized using various methods, including matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) imaging, while consuming only a few milligrams of starting materials in total. Furthermore, the feasibility of culturing cancer cells on the modified spots and quantifying the effect of MEK suppression is demonstrated. The miniaturized synthesis platform lays a foundation for high-throughput in situ biological screening of potent PROTACs for potential anticancer activity and offers the potential for accelerating the drug discovery process by integrating miniaturized synthesis and biological steps on the same array.

Citing Articles

Targeted protein degradation: advances in drug discovery and clinical practice.

Zhong G, Chang X, Xie W, Zhou X Signal Transduct Target Ther. 2024; 9(1):308.

PMID: 39500878 PMC: 11539257. DOI: 10.1038/s41392-024-02004-x.


Electrode Droplet Microarray (eDMA): An Impedance Platform for Label-Free Parallel Monitoring of Cellular Drug Response in Nanoliter Droplets.

Zhou M, Urrutia Gomez J, Mandsberg N, Liu S, Schmidt S, Meier M Adv Healthc Mater. 2024; 14(3):e2402046.

PMID: 39403791 PMC: 11773094. DOI: 10.1002/adhm.202402046.


Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed.

Kanbar K, El Darzi R, Jaalouk D Front Genet. 2024; 15:1434002.

PMID: 39144725 PMC: 11321987. DOI: 10.3389/fgene.2024.1434002.